Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction.

Koo KM, Wang J, Richards RS, Farrell A, Yaxley JW, Samaratunga H, Teloken PE, Roberts MJ, Coughlin GD, Lavin MF, Mainwaring PN, Wang Y, Gardiner RA, Trau M.

ACS Nano. 2018 Jul 26. doi: 10.1021/acsnano.8b03698. [Epub ahead of print]

PMID:
30028592
2.

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study.

Coughlin GD, Yaxley JW, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Teloken P, Dunglison N, Williams S, Lavin MF, Gardiner RA.

Lancet Oncol. 2018 Aug;19(8):1051-1060. doi: 10.1016/S1470-2045(18)30357-7. Epub 2018 Jul 17.

PMID:
30017351
3.

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation.

Roberts MJ, Richards RS, Chow CWK, Buck M, Yaxley J, Lavin MF, Schirra HJ, Gardiner RA.

Prostate Int. 2017 Dec;5(4):149-157. doi: 10.1016/j.prnil.2017.03.005. Epub 2017 Mar 23.

4.

Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.

Gordon LG, Tuffaha HW, James R, Keller AT, Lowe A, Scuffham PA, Gardiner RA.

Urol Oncol. 2018 Mar;36(3):91.e7-91.e15. doi: 10.1016/j.urolonc.2017.10.024. Epub 2017 Nov 21.

PMID:
29169847
5.

Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting.

Kim CS, Lee JY, Chung BH, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, Gardiner RA, Moretti K, Cooperberg M, Carroll P, Mun SK, Hinotsu S, Hirao Y, Ozono S, Horie S, Onozawa M, Kitagawa Y, Kitamura T, Namiki M, Akaza H.

Prostate Int. 2017 Sep;5(3):95-103. doi: 10.1016/j.prnil.2017.03.006. Epub 2017 Mar 29.

6.

PSA testing for men at average risk of prostate cancer.

Armstrong BK, Barry MJ, Frydenberg M, Gardiner RA, Haines I, Carter SM.

Public Health Res Pract. 2017 Jul 26;27(3). pii: 2731721. doi: 10.17061/phrp2731721.

7.

Randomized controlled trial of a peer led multimodal intervention for men with prostate cancer to increase exercise participation.

Galvão DA, Newton RU, Girgis A, Lepore SJ, Stiller A, Mihalopoulos C, Gardiner RA, Taaffe DR, Occhipinti S, Chambers SK.

Psychooncology. 2018 Jan;27(1):199-207. doi: 10.1002/pon.4495. Epub 2017 Jul 27.

PMID:
28685892
8.

What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?

Mervin MC, Lowe A, Gardiner RA, Smith DP, Aitken J, Chambers SK, Gordon LG.

Asia Pac J Clin Oncol. 2017 Jun;13(3):152-159. doi: 10.1111/ajco.12663. Epub 2017 Mar 16.

PMID:
28303657
9.

Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study.

Zajdlewicz L, Hyde MK, Lepore SJ, Gardiner RA, Chambers SK.

Cancer Nurs. 2017 Sep/Oct;40(5):412-419. doi: 10.1097/NCC.0000000000000432.

PMID:
28282307
10.

Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.

Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, Wall BA, Cormie P, Bolam KA, Galvão DA.

Eur Urol. 2017 Aug;72(2):293-299. doi: 10.1016/j.eururo.2017.02.019. Epub 2017 Feb 27.

11.

Assessing robot-assisted laparoscopic prostatectomy - Authors' reply.

Yaxley JW, Coughlin GD, Chambers SK, Dunglison N, Gardiner RA.

Lancet. 2017 Feb 25;389(10071):800-801. doi: 10.1016/S0140-6736(17)30508-1. No abstract available.

PMID:
28248170
12.

A randomised control trial of salvage radiotherapy and androgen deprivation therapy following prostatectomy: commentary on five year follow-up findings.

Williams S, Yaxley JW, Coughlin GD, Gardiner RA.

Transl Androl Urol. 2016 Dec;5(6):971-973. doi: 10.21037/tau.2016.11.15. No abstract available.

13.

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.

Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP.

J Clin Oncol. 2017 Jan 20;35(3):291-297. doi: 10.1200/JCO.2016.68.8788. Epub 2016 Nov 21.

PMID:
27870567
14.

Impact of branding on public awareness of healthcare-related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand.

Gianduzzo TR, Gardiner RA, Rashid P, Young R, Frydenberg M, Kelly S.

BJU Int. 2016 Oct;118 Suppl 3:23-29. doi: 10.1111/bju.13469.

15.

Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.

Roberts MJ, Richards RS, Chow CW, Doi SA, Schirra HJ, Buck M, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA.

Prostate Int. 2016 Sep;4(3):97-102. doi: 10.1016/j.prnil.2016.04.002. Epub 2016 May 5.

16.

Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.

Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J.

BJU Int. 2017 Jul;120(1):56-60. doi: 10.1111/bju.13659. Epub 2016 Oct 7.

17.

Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks.

Thomas AA, Pearce A, Sharp L, Gardiner RA, Chambers S, Aitken J, Molcho M, Baade P.

Asia Pac J Clin Oncol. 2017 Apr;13(2):e31-e40. doi: 10.1111/ajco.12570. Epub 2016 Aug 25.

PMID:
27558311
18.

Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study.

Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ, Perry-Keene J, Lavin MF, Gardiner RA.

Lancet. 2016 Sep 10;388(10049):1057-1066. doi: 10.1016/S0140-6736(16)30592-X. Epub 2016 Jul 26.

PMID:
27474375
19.

Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.

Roberts MJ, Yaxley JW, Coughlin GD, Gianduzzo TR, Esler RC, Dunglison NT, Chambers SK, Medcraft RJ, Chow CW, Schirra HJ, Richards RS, Kienzle N, Lu M, Brereton I, Samaratunga H, Perry-Keene J, Payton D, Oyama C, Doi SA, Lavin MF, Gardiner RA.

Contemp Clin Trials. 2016 Sep;50:16-20. doi: 10.1016/j.cct.2016.06.014. Epub 2016 Jun 28.

PMID:
27370230
20.

The role of mindfulness in distress and quality of life for men with advanced prostate cancer.

Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, Stockler MR, Lepore SJ, Frydenberg M, Gardiner RA, Davis ID, Smith DP.

Qual Life Res. 2016 Dec;25(12):3027-3035. Epub 2016 Jun 17.

21.

Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer.

Gardiner RA, Mainwaring P, Lavin MF.

Eur Urol. 2016 Nov;70(5):749-750. doi: 10.1016/j.eururo.2016.05.012. Epub 2016 May 24. No abstract available.

PMID:
27234996
22.

Men's help-seeking in the first year after diagnosis of localised prostate cancer.

Hyde MK, Newton RU, Galvão DA, Gardiner RA, Occhipinti S, Lowe A, Wittert GA, Chambers SK.

Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12497. Epub 2016 Apr 25.

23.

Enhancing active surveillance of prostate cancer: the potential of exercise medicine.

Galvão DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP, Frydenberg M, Hill M, Chambers SK, Stricker P, Shannon T, Hayne D, Zopf E, Newton RU.

Nat Rev Urol. 2016 May;13(5):258-65. doi: 10.1038/nrurol.2016.46. Epub 2016 Mar 8. Review.

PMID:
26954333
24.

The global burden of major infectious complications following prostate biopsy.

Bennett HY, Roberts MJ, Doi SA, Gardiner RA.

Epidemiol Infect. 2016 Jun;144(8):1784-91. doi: 10.1017/S0950268815002885. Epub 2015 Dec 9. Review.

PMID:
26645476
25.

Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes.

Gardiner RA, Yaxley J, Pakenham KI, Green H, Mactaggart P, Watson R, Swanson C, Nicol DL.

J Clin Oncol. 2015 Dec 20;33(36):4314-5. doi: 10.1200/JCO.2015.63.5698. Epub 2015 Oct 26. No abstract available.

PMID:
26503208
26.

"What should happen before asymptomatic men decide whether or not to have a PSA test?" A report on three community juries.

Degeling C, Rychetnik L, Pickles K, Thomas R, Doust JA, Gardiner RA, Glasziou P, Newson AJ, Carter SM.

Med J Aust. 2015 Oct 19;203(8):335.

PMID:
26465698
27.

Financial toxicity: a potential side effect of prostate cancer treatment among Australian men.

Gordon LG, Walker SM, Mervin MC, Lowe A, Smith DP, Gardiner RA, Chambers SK.

Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12392. Epub 2015 Oct 1.

28.

Long-term Survival Outcomes for Men Who Provided Ejaculate Specimens for Prostate Cancer Research: Implications for Patient Management.

Ashrafi D, Baade P, Yaxley J, Roberts MJ, Williams S, Gardiner RA.

Eur Urol Focus. 2015 Sep;1(2):200-206. doi: 10.1016/j.euf.2015.04.002. Epub 2015 Jun 4.

29.

Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life.

Galvão DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A, Occhipinti S, Chambers SK.

Psychooncology. 2015 Oct;24(10):1241-1249. doi: 10.1002/pon.3882. Epub 2015 Jun 18.

PMID:
26087455
30.

Prostate Cancer Detection.

Roberts MJ, Teloken P, Chambers SK, Williams SG, Yaxley J, Samaratunga H, Frydenberg M, Gardiner RA‘.

In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2018 Jun 11.

31.

Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review.

Ilic D, Jammal W, Chiarelli P, Gardiner RA, Hughes S, Stefanovic D, Chambers SK.

Psychooncology. 2015 Oct;24(10):1303-1315. doi: 10.1002/pon.3815. Epub 2015 Apr 15.

PMID:
25873433
32.

Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium.

Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. Epub 2015 Apr 2.

33.

Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population.

Alexander KE, Chambers S, Spurdle AB, Batra J, Lose F, O'Mara TA, Gardiner RA, Aitken JF, Clements JA, Kedda MA, Janda M.

Qual Life Res. 2015 Sep;24(9):2183-93. doi: 10.1007/s11136-015-0950-6. Epub 2015 Feb 28.

PMID:
25724697
34.

Seminal fluid: a useful source of prostate cancer biomarkers?

Roberts MJ, Richards RS, Gardiner RA, Selth LA.

Biomark Med. 2015;9(2):77-80. doi: 10.2217/bmm.14.110. No abstract available.

35.

Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.

Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA.

Prostate. 2015 Apr 1;75(5):539-49. doi: 10.1002/pros.22942. Epub 2015 Jan 18.

PMID:
25597828
36.

A randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer and their female partners.

Chambers SK, Occhipinti S, Schover L, Nielsen L, Zajdlewicz L, Clutton S, Halford K, Gardiner RA, Dunn J.

Psychooncology. 2015 Jul;24(7):748-56. doi: 10.1002/pon.3726. Epub 2014 Dec 8.

PMID:
25483780
37.

Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA.

Drayton RM, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, Stoehr R, Hartmann A, Blizard S, Lavin M, Bryant HE, Martens-Uzunova ES, Jenster G, Hamdy FC, Gardiner RA, Catto JW.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):268-75. doi: 10.1158/1055-9965.EPI-14-0377. Epub 2014 Nov 12.

38.

Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers.

Selth LA, Roberts MJ, Chow CW, Marshall VR, Doi SA, Vincent AD, Butler LM, Lavin MF, Tilley WD, Gardiner RA.

Endocr Relat Cancer. 2014 Aug;21(4):L17-21. doi: 10.1530/ERC-14-0234. Epub 2014 May 23. No abstract available.

39.

Defining young in the context of prostate cancer.

Chambers SK, Lowe A, Hyde MK, Zajdlewicz L, Gardiner RA, Sandoe D, Dunn J.

Am J Mens Health. 2015 Mar;9(2):103-14. doi: 10.1177/1557988314529991. Epub 2014 Apr 29.

40.

Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies.

Cormie P, Chambers SK, Newton RU, Gardiner RA, Spry N, Taaffe DR, Joseph D, Hamid MA, Chong P, Hughes D, Hamilton K, Galvão DA.

BMC Cancer. 2014 Mar 18;14:199. doi: 10.1186/1471-2407-14-199.

41.

Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis.

Roberts MJ, Williamson DA, Hadway P, Doi SA, Gardiner RA, Paterson DL.

Int J Antimicrob Agents. 2014 Apr;43(4):301-9. doi: 10.1016/j.ijantimicag.2014.01.008. Epub 2014 Feb 9. Review.

PMID:
24630305
42.

Statins: protectors or pretenders in prostate cancer?

Moon H, Hill MM, Roberts MJ, Gardiner RA, Brown AJ.

Trends Endocrinol Metab. 2014 Apr;25(4):188-96. doi: 10.1016/j.tem.2013.12.007. Epub 2014 Jan 22. Review.

PMID:
24462080
43.

Epidemiology of prostate cancer in the Asia-Pacific region.

Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA.

Prostate Int. 2013;1(2):47-58. doi: 10.12954/PI.12014. Epub 2013 Jun 30. Review.

44.

A progress report on a prospective randomised trial of open and robotic prostatectomy.

Gardiner RA, Coughlin GD, Yaxley JW, Dunglison NT, Occhipinti S, Younie SJ, Carter RC, Williams SG, Medcraft RJ, Samaratunga HM, Perry-Keene JL, Payton DJ, Lavin MF, Chambers SK.

Eur Urol. 2014 Mar;65(3):512-5. doi: 10.1016/j.eururo.2013.10.031. Epub 2013 Oct 31.

PMID:
24215940
45.

BMCC1 is an AP-2 associated endosomal protein in prostate cancer cells.

Harris JL, Richards RS, Chow CW, Lee S, Kim M, Buck M, Teng L, Clarke R, Gardiner RA, Lavin MF.

PLoS One. 2013 Sep 6;8(9):e73880. doi: 10.1371/journal.pone.0073880. eCollection 2013.

46.

Couple distress after localised prostate cancer.

Chambers SK, Schover L, Nielsen L, Halford K, Clutton S, Gardiner RA, Dunn J, Occhipinti S.

Support Care Cancer. 2013 Nov;21(11):2967-76. doi: 10.1007/s00520-013-1868-6. Epub 2013 Jun 12.

PMID:
23756617
47.

Systematic review of research into the psychological aspects of prostate cancer in Asia: what do we know?

Chambers SK, Hyde MK, Ip DF, Dunn JC, Gardiner RA.

Asian Pac J Cancer Prev. 2013;14(4):2621-6.

48.

Prevalence and predictors of cancer specific distress in men with a family history of prostate cancer.

McDowell ME, Occhipinti S, Gardiner RA, Chambers SK.

Psychooncology. 2013 Nov;22(11):2496-504. doi: 10.1002/pon.3312. Epub 2013 May 27.

PMID:
23712946
49.

Multifocal abscesses due to multiresistant Escherichia coli after transrectal ultrasound-guided prostate biopsy.

Roberts MJ, Parambi A, Barrett L, Hadway P, Gardiner RA, Hajkowicz KM, Yaxley J.

Med J Aust. 2013 Mar 18;198(5):282-4. No abstract available.

PMID:
23496407
50.

A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer.

Chambers SK, Smith DP, Berry M, Lepore SJ, Foley E, Clutton S, McDowall R, Occhipinti S, Frydenberg M, Gardiner RA.

BMC Cancer. 2013 Feb 26;13:89. doi: 10.1186/1471-2407-13-89.

Supplemental Content

Loading ...
Support Center